NEW YORK, August 8, 2017 /PRNewswire/ --

If you want a Stock Review on CYTR, AEZS, CAPR, or CBAY then come over to and sign up for your free customized report today. In a note on Tuesday, July 11th, 2017, an analyst at Jefferies wrote that the investment firm is fundamentally positive on the Biotech sector due to three key factors: investors will come back to health care stocks as part of a "rotation and reversion" from other sectors, there are low-expectation set-ups in biotech, and consensus earnings estimates remain beatable for key sector players. This morning, has issued research reports on: CytRx Corp. (NASDAQ: CYTR), Aeterna Zentaris Inc. (NASDAQ: AEZS), Capricor Therapeutics Inc. (NASDAQ: CAPR), and Cymabay Therapeutics Inc. (NASDAQ: CBAY). Daily Stock Tracker published free research reports on these stocks today at:


Los Angeles, California headquartered CytRx Corp.'s shares jumped 8.75%, closing Monday's trading session at $0.69. The stock recorded a trading volume of 7.77 million shares. The Company's shares have surged 24.56% in the last month, 42.40% over the previous three months, and 84.07% since the start of this year. The stock is trading 5.32% above its 50-day moving average and 34.26% above its 200-day moving average. Additionally, shares of CytRx, which operates as a biopharmaceutical research and development company specializing in oncology, have a Relative Strength Index (RSI) of 51.38.

On August 03rd, 2017, CytRx announced financial results for the quarter ended June 30th, 2017. Net loss for Q2 2017 was $14.4 million, or $(0.10) per share; R&D expenses were $6.2 million; and general and administrative expenses were $3.1 million. The Company also reported cash, cash equivalents, and short-term investments of $55.0 million as of June 30th, 2017. See our free and comprehensive research report on CYTR at:

Aeterna Zentaris 

On Monday, shares in Summerville, South Carolina headquartered Aeterna Zentaris Inc. recorded a trading volume of 845,874 shares. The stock dropped 3.55%, ending the day at $1.90. The Company's shares have skyrocketed 88.12% in the past month and 111.11% in the previous three months. The stock is trading above its 50-day moving average by 44.11%. Furthermore, shares of Aeterna Zentaris, which engages in developing and commercializing novel treatments in oncology, endocrinology, and women's health, have an RSI of 55.21.

On July 19th, 2017, research firm Maxim Group reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $2 a share to $4 a share.

On August 04th, 2017, Aeterna Zentaris announced that it will release its Q2 2017 financial and operating results after market close on August 10th, 2017. The Company will host a conference call to discuss these results on August 11th, 2017, at 8:30 a.m. ET. AEZS free research report is just a click away at:

Capricor Therapeutics 

Beverly Hills, California headquartered Capricor Therapeutics Inc.'s stock finished the day 0.88% lower at $1.13 with a total trading volume of 337,182 shares. The Company's shares have advanced 68.66% in the last one month. The stock is trading above its 50-day moving average by 30.01%. Additionally, shares of Capricor Therapeutics, which focuses on the discovery, development, and commercialization of novel therapeutics primarily for the treatment of cardiovascular diseases, have an RSI of 54.78.

On August 03rd, 2017, Capricor Therapeutics announced that it will report Q2 2017 financial results shortly after the NASDAQ market close on August 10th, 2017. Management will host a webcast and conference call at 4:30 p.m. ET on that same day. Sign up for your complimentary report on CAPR at:

Cymabay Therapeutics 

Shares in Newark, California headquartered Cymabay Therapeutics Inc. ended yesterday's session 0.56% higher at $7.16. The stock recorded a trading volume of 316,806 shares. The Company's shares have advanced 26.73% in the last one month, 100.56% over the previous three months, and 313.87% since the start of this year. The stock is trading 24.10% and 105.46% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Cymabay Therapeutics, which focuses on developing and commercializing therapies to treat specialty and orphan diseases, have an RSI of 59.22.

On July 20th, 2017, research firm Oppenheimer reiterated its 'Outperform' rating on the Company's stock with an increase of the target price from $8 a share to $15 a share.

On July 24th, 2017, Cymabay Therapeutics announced the closing of its previously announced underwritten public offering of its common stock. The Company sold 14,950,000 shares of its common stock in the offering, including 1,950,000 shares pursuant to the full exercise of the underwriters' option to purchase additional shares, at a public offering price of $6.50 per share before underwriting discounts and commissions. Register for free on and download the latest research report on CBAY at:


Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

DST has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA